3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Neoplasms
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Urinary Bladder Neoplasms
1
Solid Tumor
1
Ovarian Neoplasms
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
NSCLC
1
Myeloproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid
1
Leukemia
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Glioblastoma
1
Bone Marrow Diseases
1
Advanced Solid Tumor
1
Adenocarcinoma of Lung
1
Interventions
ponatinib
4
pembrolizumab
3
Rituximab
3
Gemcitabine
3
Cyclophosphamide
3
130-nm albumin-bound paclitaxel
3
pralsetinib
2
napabucasin
2
Vincristine
2
Prednisone
2
Irinotecan
2
Imatinib Mesylate
2
Etoposide
2
Doxorubicin
2
Carboplatin
2
Brentuximab Vedotin
2
tetulomab tetraxetan lu-177
1
ruxolitinib
1
ricolinostat
1
pomalidomide
1
pamiparib
1
nirogacestat
1
nilotinib
1
ibritumomab tiuxetan
1
denileukin diftitox
1
bosutinib
1
blinatumomab
1
Vorinostat
1
Temozolomide
1
Radiation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Neoplasms by Histologic Type
×
BID protein, human
×
Clear all
NCT02627677
2021-11-26
OPTIC-2L
Takeda
Phase 3
Terminated
44 enrolled
22 charts